替吉奥持续口服治疗转移性肝癌的临床观察  

Treatment of metastatic liver cancer with continuous oral tegafur

作　　者：薛耀辉[1] 付相建[1] 杨光华[1] 

机构地区：[1]解放军324医院中医肿瘤科,重庆400020

出　　处：《西南国防医药》2011年第8期851-852,共2页Medical Journal of National Defending Forces in Southwest China

摘　　要：目的观察替吉奥持续口服治疗转移性肝癌的有效性和安全性。方法选择40例CT检查确诊转移性肝癌患者,均为肝内弥漫性转移,肝内转移瘤数目5～15个,直径2.0～5.5 cm;男性26例,女性14例,年龄52～71岁。服用替吉奥胶囊90.8 mg/d,持续服用至病情进展无法服药,每月复查血常规,每隔3个月复查腹部CT及肝肾功,评价疗效及毒性。结果 PR 5例,SD 26例,PD 9例,反应率为77.5%,疾病进展时间(TTP)为8.1个月,中位生存时间(MST)为19个月。12例服药后出现轻度恶心,所有患者疾病进展前血常规、肝肾功各项指标均无显著变化。结论替吉奥持续口服治疗转移性肝癌,能延缓病情发展,毒副作用轻微,费用低廉,可作为转移性肝癌的维持治疗。Objective To observe the efficacy and safety of continuous oral tegafur on metastatic liver cancer.Methods 40 patients with diffuse metastatic liver cancer confirmed by CT were selected.The number of intrahepatic metastasis ranged from 5 to 15 per person,and the diameter ranged from 2 to 5.5 cm.They continuously took tegafur capsule at 90.8 mg daily until oral administration could not move on due to the progression of pathogenetic condition.All the patients received blood routine re-examination monthly as well as abdominal CT,hepatic and renal function re-examination every 3 months.Curative effects and drug toxicity were evaluated.Results Partial remission（PR） achieved in 5 cases,stable disease（SD） in 26 cases,progressive disease（PD） in 9 cases,and the responsive rate was 77.5%.Time-to-progression（TTP） was 8.1 months,and median survival time（MST） was 19 months.Only 12 patients had mild nausea and vomitting after administration.Each index of blood routine examination,hepatic and renal function did not changed significantly before PD.Conclusion Treatment of metastatic liver cancer with continuous oral tegafur can delay the progression of pathogenetic condition.It is of slight adverse reaction and low cost,and therefore can be used as a maintenance therapy for metastatic liver cancer.

关 键 词：转移性肝癌 替吉奥 口服 

分 类 号：R735.7[医药卫生—肿瘤]